Skip to Content

Join the 'Cobicistat' group to help and get support from people like you.

Cobicistat News

HIV Infection Seems to Affect Nervous System

Posted 13 Jun 2016 by Drugs.com

MONDAY, June 13, 2016 – Many newly infected HIV patients experience neurological problems, but they tend to be mild and they subside after antiretroviral drugs are given, a new study finds. "We were surprised that neurologic findings were so pervasive in participants diagnosed with very recent HIV infection," said study author Dr. Joanna Hellmuth. She is a clinical fellow in the department of neurology at the University of California, San Francisco (UCSF). "While the findings were mild, it is clear that HIV affects the nervous system within days of infection," she said in a university news release. "Since the majority of these neurologic issues were resolved with treatment, our study reinforces recommendations that people at risk for HIV test often and start antiretroviral treatment immediately if they are infected," Hellmuth added. Among 139 people in Thailand infected with HIV three ... Read more

Related support groups: Peripheral Neuropathy, Harvoni, HIV Infection, Atripla, Pre-Exposure Prophylaxis, Incivek, Truvada, Stribild, Complera, Triumeq, Autonomic Neuropathy, Baraclude, Victrelis, Genvoya, Zepatier, Viread, Kaletra, Viekira Pak, Norvir, Daklinza

HIV Can Persist in Body Despite Drug Therapy

Posted 27 Jan 2016 by Drugs.com

WEDNESDAY, Jan. 27, 2016 – Even when blood tests of HIV patients on antiretroviral drugs show no sign of the AIDS-causing virus, it can still be replicating in lymphoid tissue, researchers report. The study offers important new insight into how HIV persists in the body despite treatment with the powerful drugs, according to the team of international researchers led by Northwestern University's Feinberg School of Medicine in Chicago. To reach their finding, they examined viral sequences in samples of lymph node and blood cells from three HIV-infected patients who had no detectable virus in their blood. And what they found was that a viral reservoir in lymphoid tissue, which scientists believed held long-lived infected cells in a resting state, was being constantly replenished with infected cells. "The challenge is to deliver drugs at clinically effective concentrations to where the ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Sovaldi, Pre-Exposure Prophylaxis, Incivek, Truvada, Stribild, Complera, Triumeq, Baraclude, Victrelis, Genvoya, Sofosbuvir, Viread, Kaletra, Viekira Pak, Norvir, Daklinza, Entecavir

Drug Makers, Governments Sign Deal to Fight Drug-Resistant Infections

Posted 21 Jan 2016 by Drugs.com

A groundbreaking agreement between the drug industry and governments to work together to fight drug-resistant "superbugs" is expected to be announced Thursday. Under the deal, 74 drug makers, 11 diagnostic test makers, and nine industry groups pledge to work with each other and 16 countries to prevent and improve treatment of drug-resistant infections, the Associated Press reported. These infections are a serious threat to millions of people worldwide and a number of factors contribute to the problem, including overuse of antibiotics, declining drug industry research, and few new medicines to combat bacteria, viruses, parasites and fungi. The new deal – scheduled to be announced at the World Economic Forum in Davos, Switzerland – is the first to outline how the drug industry and governments should team up to prevent more drugs from becoming ineffective, to spur development of new ... Read more

Related support groups: Doxycycline, Cephalexin, Bactrim, Cipro, Ciprofloxacin, Levaquin, Keflex, Sulfamethoxazole, Minocycline, Lamisil, Nystatin, Levofloxacin, Bactrim DS, Cefdinir, Terbinafine, Tetracycline, Avelox, Sulfamethoxazole/Trimethoprim, Cefuroxime, Sulfasalazine

FDA Approves Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) for HIV

Posted 5 Nov 2015 by Drugs.com

The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. The CDC estimates that 1.2 million persons ages 13 years and older are living with HIV infection, and that more than another 150,000 persons in this age range have HIV but are unaware of their infection. Over the past decade, the number of people living with HIV has increased, while the annual number of new HIV infections has remained relatively stable. “Today’s approval of a fixed dose combination containing a new form of tenofovir provides another effective, once daily complete regimen for patients with HIV-1 infection,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in th ... Read more

Related support groups: HIV Infection, Stribild, Genvoya, Viread, Tenofovir, Elvitegravir, Emtriva, Tybost, Cobicistat, Vitekta, Emtricitabine, Cobicistat/elvitegravir/emtricitabine/tenofovir Alafenamide, Cobicistat/elvitegravir/emtricitabine/tenofovir

HIV Therapy May Also Lower Risk for Hepatitis B, Study Says

Posted 12 Oct 2015 by Drugs.com

MONDAY, Oct. 12, 2015 – Not only does effective HIV therapy thwart the AIDS-causing virus, it may also reduce the risk for hepatitis B infection, a new study says. "What this means to us is that effective HIV therapy appears to restore an impairment in the immune response that protects someone with HIV from acquiring hepatitis B infection," study senior author Dr. Chloe Thio, a professor of medicine at Johns Hopkins University School of Medicine, said in a university news release. The study, published in the October issue of Annals of Internal Medicine, involved 2,400 gay and bisexual men who were enrolled in the Multicenter AIDS Cohort Study. Researchers found that the men successfully treated with HIV therapy had the same risk for hepatitis B infection as the men who did not have HIV. Hepatitis B is a virus that can damage the liver. The study showed HIV-positive men on HIV therapy ... Read more

Related support groups: Harvoni, HIV Infection, Valtrex, Acyclovir, Atripla, Hepatitis B, Sovaldi, Valacyclovir, Ribavirin, Pre-Exposure Prophylaxis, Incivek, Zovirax, Truvada, Pegasys, Stribild, Triumeq, Complera, Baraclude, Victrelis, Famciclovir

Many U.S. AIDS Patients Still Die When 'Opportunistic' Infections Strike

Posted 1 Jul 2015 by Drugs.com

WEDNESDAY, July 1, 2015 – Even after the advent of powerful medications for suppressing HIV, a new study finds that more than one-third of people in San Francisco who were diagnosed with an AIDS-related infection died within five years. "The main cause of mortality arises from people stopping treatment entirely," said Dr. Robert Grant, a professor at the University of California, San Francisco, who reviewed the findings but was not involved in the research. When HIV treatment lapses, so-called "opportunistic" infections and illnesses can arise, posing a real threat to patients' health, he explained. The bottom line, according to Grant, is that there is still "a long way to go" in prolonging the lives of Americans with HIV/AIDS. The new study was led by Dr. Sandra Schwarcz, associate professor of epidemiology and biostatistics at the University of California, San Francisco. She and her ... Read more

Related support groups: Harvoni, HIV Infection, Tamiflu, Atripla, Sovaldi, Pre-Exposure Prophylaxis, Incivek, Truvada, Stribild, Complera, Triumeq, Baraclude, Victrelis, Mycobacterium avium-intracellulare, Sofosbuvir, Mycobacterium avium-intracellulare - Treatment, Viread, Kaletra, Oseltamivir, Norvir

Sequence of Shots May Lead to Effective HIV Vaccine, Mouse Study Finds

Posted 25 Jun 2015 by Drugs.com

THURSDAY, June 25, 2015 – It's unlikely that a single vaccine would ever enable the body to neutralize the HIV virus, but a sequence of immunizations might hold the key, a new mouse study suggests. The immune system could be guided in a series of steps to develop a special type of HIV-fighting antibody, a team of researchers said. Each immunization would be customized for specific stages of the immune system's response to the virus. In the end, the series of shots would result in the production of broadly neutralizing antibodies capable of fighting HIV, the authors said. "As HIV mutates in a patient, the immune system continually adapts. In some patients, this process produces broadly neutralizing antibodies, which are unusual antibodies that can bind to and neutralize a wide range of globally occurring HIV variants. These are the antibodies we want to try to elicit with a vaccine," ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Sovaldi, Pre-Exposure Prophylaxis, Incivek, Truvada, Stribild, Complera, Triumeq, Baraclude, Victrelis, Sofosbuvir, Viread, Kaletra, Entecavir, Norvir, Tenofovir, Telaprevir, Lamivudine

FDA Approves Prezcobix (darunavir and cobicistat) for HIV-1 Infection in Adults

Posted 29 Jan 2015 by Drugs.com

TITUSVILLE, N.J., Jan. 29, 2015 /PRNewswire/ – Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the U.S. Food and Drug Administration (FDA) has approved Prezcobix (darunavir 800 mg/cobicistat 150 mg) tablets, an HIV-1 protease inhibitor combined with a CYP3A4 inhibitor, for the treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral agents for treatment-naive and treatment-experienced adults with no darunavir resistance-associated substitutions.[1] Prezcobix is a once-daily, fixed-dose antiretroviral combination tablet containing 800 mg of darunavir, marketed as PREZISTA® in the United States, and 150 mg of cobicistat, a pharmacokinetic enhancer or "boosting" agent, developed and marketed as Tybost® by Gilead Sciences, Inc., taken orally with other HIV-1 medications and with food. "Additional options remain an i ... Read more

Related support groups: HIV Infection, Darunavir, Cobicistat

FDA Approves Evotaz (atazanavir and cobicistat) for HIV-1 Infection in Adults

Posted 29 Jan 2015 by Drugs.com

PRINCETON, N.J. – January 29, 2015 --(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Evotaz (atazanavir 300 mg and cobicistat 150 mg) tablets in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. Evotaz is coformulated to be one pill, once-daily, combining the protease inhibitor atazanavir, which is marketed as Reyataz (atazanavir 200 mg/300 mg) capsules, and cobicistat, a pharmacokinetic enhancer marketed by Gilead Sciences, Inc. Today’s approval offers patients living with HIV an innovative treatment option that delivers proven suppression (HIV-1 RNA 70mL/min, a mean baseline plasma HIV-1 RNA of 4.8 log10 copies/mL, and a mean baseline CD4+ cell count of 352 cells/mm. At 48 weeks, 85% of patients in the Evotaz arm achieved HIV-1 RNA levels of Read more

Related support groups: HIV Infection, Atazanavir, Cobicistat

Ask a Question

Further Information

Related Condition Support Groups

HIV Infection

Related Drug Support Groups

Tybost

Cobicistat Patient Information at Drugs.com